查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1948950

SMA注射劑市場按作用機制、給藥途徑、適應症和最終用戶分類，全球預測（2026-2032年）

Injections for SMA Market by Mechanism Of Action, Route Of Administration, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，脊髓性肌肉萎縮症 (SMA) 注射劑市值將達到 45.8 億美元，到 2026 年將成長至 51 億美元，到 2032 年將達到 112.4 億美元，複合年成長率為 13.67%。

主要市場統計數據
基準年 2025 45.8億美元
預計年份：2026年 51億美元
預測年份：2032年 112.4億美元
複合年成長率 (%) 13.67%

為脊髓性肌肉萎縮症（SMA）注射療法建立清晰的策略框架，闡明影響該療法的臨床、物流和相關人員動態，為決策者提供背景資訊。

脊髓性肌肉萎縮症（SMA）曾是一種幾乎必然致命的兒童疾病，如今已發展成為一個複雜的治療領域，其特點是技術的飛速發展、精細的臨床管理以及不斷演進的患者照護模式。注射型疾病修正治療的出現重塑了臨床實踐，要求臨床醫生、支付方、生產商和看護者適應新的給藥通訊協定、安全監測框架和長期療效追蹤。過去十年，治療方法創新已將討論的重點從主要針對症狀的緩解治療轉向旨在改變疾病本身生物學機制的干涉措施，而這種演變也帶來了一系列獨特的運營、監管和市場進入挑戰。

分子方法、給藥方式和醫療保健系統重塑的進步如何融合，正在重塑注射型脊髓性肌肉萎縮症（SMA）治療給藥模式的未來？

分子生物學、遞送技術和醫療保健系統組織的進步正在改變注射型脊髓性肌肉萎縮症（SMA）的治療格局。基因為基礎的介入和反義寡核苷酸療法已日趨成熟，如今，作用機制的比較主要主導患者特徵、給藥物流和長期安全性監測要求。因此，治療路徑正在進行重組，以支持早期診斷、協調的多學科管理以及長期功能和生活品質結果的計劃性隨訪。

評估2010年代中期貿易政策調適對注射SMA治療相關的供應鏈結構、籌資策略和製造地決策的影響

貿易和關稅政策的變化會波及到支持脊髓性肌肉萎縮症（SMA）注射療法的專業供應鏈，影響原料採購、生產投入和跨境物流的成本效益。 2025年，美國關稅調整和國際報復行動引發了關於最終灌裝和包裝流程位置、關鍵試劑籌資策略以及長期供應協議建構等方面的新考量。擁有垂直整合生產流程的企業和擁有多元化供應商網路的企業，由於對載體、脂質體和特殊輔料等進口成分的依賴程度不同，其營運受到的影響也各不相同。

對注射型 SMA 治療進行全面的細分分析，將作用機制、給藥途徑、臨床亞型、臨床環境和分銷管道與營運和策略重點聯繫起來。

這種細分方法為解讀注射型脊髓性肌肉萎縮症（SMA）治療的臨床和商業性趨勢提供了一個系統性的觀點，它能夠識別作用機制、給藥途徑、臨床適應症、臨床環境和分銷管道等方面的差異。作用機制分析比較了反義寡核苷酸療法和基因療法，評估了不同的生物療法如何影響給藥間隔、安全監測需求和長期照護。從給藥途徑的角度來看，鞘內注射和靜脈注射之間的差異揭示了不同的基礎設施需求、臨床醫生技能要求以及患者準備情況，這些都會顯著影響治療的普及和護理流程。

區域策略資訊：分析管理體制、醫療體係成熟度和基礎設施的差異如何影響注射用脊髓性肌肉萎縮症（SMA）治療藥物的供應和取得。

受法規結構、醫療體系組織結構和當地臨床能力的影響，區域趨勢為注射型脊髓性肌肉萎縮症（SMA）治療藥物的引入創造了不同的運作環境。在美洲地區，臨床生態系統的特點是擁有先進的診斷網路、成熟的卓越中心以及優先考慮持續臨床獲益證據的支付方結構。這些因素支持複雜治療模式的快速應用，同時加強對真實世界療效的監測。整合式醫療協調和與支付方談判的需求尤其突出，相關人員通常致力於證明療效隨時間推移而改善，以確保醫保覆蓋並擴大患者群體。

在那些將先進的治療方法知識、生產韌性和真實世界證據能力相結合，以支持永續採用和獲取的組織中，出現了一種清晰的戰略優勢模式。

SMA注射劑生態系統中的領導者展現出一致的能力模式，並將其轉化為競爭優勢：深厚的先進技術專長、整合的臨床開發管道以及靈活的生產策略。持續投資於載體和寡核苷酸平台技術並配備完善的藥物監測系統的公司，更有能力應對複雜的監管要求，並產生支付方日益重視的長期安全性數據。從學術合作到契約製造聯盟等策略夥伴關係，能夠拓展企業能力並加速臨床轉化。同時，優先參與專科藥局網路和卓越中心專案的公司，通常能夠更順利地完成產品上市。

實際可行、優先排序的策略性舉措，整合臨床、營運和商業能力，以加速注射型脊髓性肌肉萎縮症（SMA）治療藥物的普及並確保其永續供應。

產業領導者應優先考慮整合臨床開發、營運準備和支付方參與，以確保患者能夠持續獲得注射型脊髓性肌肉萎縮症（SMA）治療。首先，將真實世界證據收集納入核准後計畫和註冊登記，將增強藥物的價值提案，支持按績效付費的合約模式，同時也有助於制定安全監測通訊協定和長期照護計畫。其次，擴大臨床醫生培訓計畫並對給藥中心進行認證，將減少操作差異，改善患者體驗，尤其對於需要專業知識的鞘內給藥。第三，投資於分散式生產和二級供應商認證，將降低政策和關稅風險，縮短前置作業時間，並保障區域供應的連續性。

採用透明的混合方法研究策略，結合對關鍵相關人員的訪談、監管和臨床文獻綜述以及同行檢驗，以獲得可操作的見解。

本研究綜合分析採用混合方法，將質性研究的初步發現與對臨床、監管和營運資訊來源的嚴格審查相結合。一級資訊來源包括對經驗豐富的鞘內和靜脈注射醫生、供應鏈主管、專科藥房運營人員以及患者權益相關人員的結構化訪談，以提供關於治療路徑、培訓需求和分銷挑戰的實地觀點。次要研究包括對同儕審查的臨床研究、監管指導文件、臨床試驗註冊庫和報銷政策公告進行系統性審查，以驗證有關安全性、給藥通訊協定和支付方期望的證據。

簡要概述強調了臨床、生產和支付方等各相關人員之間密切合作的必要性，以實現注射型SMA治療給患者帶來的持續獲益。

注射型SMA治療領域正處於轉折點，科學進步、給藥創新和系統層面的準備將共同決定患者的用藥機會和長期治療效果。有效的策略需要同步進行證據生成，並兼顧臨床專案設計、生產規模化、分銷管道的韌性以及與支付方的協調。能夠認知到特定機制的臨床需求、給藥途徑的物流以及醫療環境物流情況之間相互依存關係的相關人員，將更有能力將治療潛力轉化為切實的患者獲益。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依作用機轉分類的SMA注射劑市場

  • 反義寡核苷酸療法
  • 基因治療

9. 按給藥途徑分類的SMA注射劑市場

  • 鞘內注射
  • 靜脈注射

第10章 依適應症分類的SMA注射劑市場

  • 一型
  • II 型
  • III型
  • 四型

第11章 以最終用戶分類的SMA注射劑市場

  • 診所
    • 門診部
    • 專科診所
  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院

12. 按地區分類的SMA注射劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的SMA注射劑市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國SMA注射劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國脊髓性肌肉萎縮症注射市場

第16章：中國SMA注射劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Astellas Pharma Inc.
  • Audentes Therapeutics, Inc.
  • Audentes Therapeutics, Inc.
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • BridgeBio Pharma, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Ionis Pharmaceuticals, Inc.
  • NMD Pharma A/S
  • Novartis AG
  • Novartis Gene Therapies, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Regenxbio Inc.
  • Sarepta Therapeutics, Inc.
  • Scholar Rock, Inc.
  • Shionogi & Co., Ltd.
Product Code: MRR-4F7A6D4FB902

The Injections for SMA Market was valued at USD 4.58 billion in 2025 and is projected to grow to USD 5.10 billion in 2026, with a CAGR of 13.67%, reaching USD 11.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.58 billion
Estimated Year [2026] USD 5.10 billion
Forecast Year [2032] USD 11.24 billion
CAGR (%) 13.67%

A clear strategic framing of the clinical, logistical, and stakeholder dynamics shaping injection-based therapies for spinal muscular atrophy that set the context for decision-makers

Spinal muscular atrophy (SMA) has transformed from a uniformly fatal pediatric condition into a complex therapeutic area defined by rapid technological advances, nuanced clinical management, and evolving patient care paradigms. The emergence of injection-based disease-modifying therapies has reoriented clinical practice, requiring clinicians, payers, manufacturers, and caregivers to adapt to new administration protocols, safety monitoring frameworks, and long-term outcome tracking. Over the last decade, therapeutic innovation has shifted conversations from primarily symptomatic care toward interventions designed to alter disease biology, and this evolution has created a distinct set of operational, regulatory, and market-access challenges.

This introduction frames the injectable therapeutics landscape by mapping the interplay between clinical evidence generation, route-of-administration logistics, and stakeholder decision-making. It highlights the necessity of integrating clinical program design with manufacturing scalability and distribution resilience. The content underscores how patient-centric care models and multidisciplinary treatment teams are becoming central to effective deployment of intrathecal and intravenous therapies. Ultimately, this section positions readers to understand subsequent analyses by clarifying the medical, logistical, and strategic variables that define successful commercialization and sustained patient benefit in SMA injection therapies.

How converging advances in molecular approaches, delivery methods, and health-system redesign are reshaping the future of injectable SMA treatment delivery models

The injectable SMA landscape is undergoing transformative shifts driven by convergent advances in molecular biology, delivery technologies, and health-system organization. Gene-based interventions and antisense oligonucleotide approaches have matured to the point where comparative decision-making between mechanisms of action is dominated by patient characteristics, dosing logistics, and long-term safety monitoring requirements. As a result, care pathways are being reconfigured to support earlier diagnosis, coordinated multidisciplinary management, and programmatic follow-up that captures functional and quality-of-life outcomes over time.

Concurrently, delivery innovations are influencing where and how treatments are administered. Intrathecal delivery protocols have prompted investments in specialized clinical infrastructure and clinician training, while intravenous administration modalities are prompting consideration of infusion centers and homecare readiness. Payers and health systems are responding to outcomes-based evidence demands by emphasizing real-world evidence collection and registries. Furthermore, supply-chain resilience and manufacturing footprint are now strategic differentiators as stakeholders assess the ability to deliver consistent therapy access across geographies. Together, these shifts are reshaping clinical trial design, regulatory engagement, and commercialization tactics, compelling a systems-level approach to bringing injectable SMA therapies to patients.

Assessment of how mid-decade trade policy adjustments influenced supply-chain architecture, sourcing strategies, and manufacturing footprint decisions relevant to injectable SMA therapies

Policy changes in trade and tariff regimes have the potential to ripple through the specialized supply chains that support injectable therapies for SMA, affecting raw material sourcing, manufacturing inputs, and the cost-efficiency of cross-border logistics. In 2025, tariff adjustments in the United States and reciprocal measures internationally introduced new considerations around the location of final fill-finish operations, procurement strategies for critical reagents, and the structuring of long-term supplier agreements. Organizations with vertically integrated manufacturing and those that have diversified supplier networks experienced differing operational impacts depending on their dependence on imported components for vectors, lipids, and specialty excipients.

In response, companies accelerated strategies to mitigate tariff-driven risk by increasing local content where feasible, negotiating longer-term supply contracts, and accelerating qualification of secondary suppliers. These adaptations also incentivized investment in regional manufacturing capacity and cold-chain redundancies to preserve continuity of care. Payers and providers likewise began to re-evaluate contracting models to reflect the increased complexity of cross-border supply economics, and some organizations prioritized contractual clauses that allocate tariff risk. While tariffs introduced incremental costs and logistical complexity, their most consequential effect was to catalyze strategic shifts in sourcing and manufacturing footprints, prompting stakeholders to place greater emphasis on supply security and to redesign procurement governance frameworks.

Comprehensive segmentation insights that link mechanism, administration route, clinical subtype, care setting, and distribution pathway to operational and strategic priorities for injectable SMA therapies

Segmentation provides a structured lens through which to interpret clinical and commercial dynamics in injectable SMA therapies, acknowledging variation across mechanism of action, administration route, clinical indication, care setting, and distribution pathway. Analysis by mechanism of action contrasts Antisense Oligonucleotide Therapy with Gene Therapy, evaluating how differing biological modalities shape dosing cadence, safety-monitoring requirements, and long-term care implications. When viewed through the prism of route of administration, distinctions between Intrathecal Injection and Intravenous Injection reveal diverging infrastructure demands, clinician skill requirements, and patient suitability considerations that materially affect treatment adoption and care workflows.

Indication-based segmentation across Type I, Type II, Type III, and Type IV captures the heterogeneity of disease onset and progression, which in turn influences timing of intervention, expected clinical outcomes, and registrational evidence strategies. Examining end-user environments clarifies operational readiness by partitioning Clinics, Homecare Settings, and Hospitals, with Clinics further segmented into Ambulatory Clinics and Specialty Clinics, and Hospitals differentiated between Private Hospitals and Public Hospitals; this reveals where investments in training, monitoring, and infusion capacity are most needed. Distribution channel segmentation distinguishes Hospital Pharmacy, Retail Pharmacy, and Specialty Pharmacy, with Hospital Pharmacy subdivided into Contract Pharmacy and In-House Pharmacy, and Retail Pharmacy categorized as Chain Pharmacy, Independent Pharmacy, and Online Pharmacy; these distinctions highlight how channel selection affects cold-chain responsibilities, patient access, and reimbursement interactions. Together, these segmentation axes enable decision-makers to tailor clinical development, commercialization, and operational plans to the nuanced needs of each patient cohort and care environment.

Regional strategic intelligence highlighting how differences in regulatory regimes, health-system maturity, and infrastructure shape delivery and access for injectable SMA therapies

Regional dynamics create distinct operational environments for deploying injectable SMA therapies, influenced by regulatory frameworks, health-system organization, and local clinical capacity. In the Americas, the clinical ecosystem is characterized by advanced diagnostic networks, established centers of excellence, and payer structures that prioritize evidence of sustained clinical benefit; these factors support rapid adoption of complex delivery models but also place heightened scrutiny on real-world outcomes. The necessity for integrated care coordination and payer negotiations is particularly pronounced, and stakeholders often focus on demonstrating longitudinal functional improvements to secure coverage and broaden access.

Europe, Middle East & Africa present a mosaic of regulatory approaches, reimbursement mechanisms, and clinical infrastructure maturity. In several European health systems, centralized HTA processes and national procurement strategies shape access timelines and post-market evidence commitments, while regions with constrained specialist resources may require innovative administration models and capacity-building initiatives. The Middle East and Africa exhibit variability in specialist availability and cold-chain infrastructure, prompting targeted investments in regional centers and training to enable equitable access. In Asia-Pacific, the landscape is driven by rapid adoption in markets with established biotech manufacturing and by emerging markets that prioritize cost-effective distribution models; here, strategic partnerships with regional manufacturers and adaptive pricing schemes often determine the pace at which newer therapies enter routine care. Awareness of these regional distinctions guides prioritization of clinical site selection, manufacturing localization, and tailored market-access strategies to ensure therapies reach appropriate patient populations efficiently.

Clear patterns of strategic advantage among organizations that align advanced modality expertise, manufacturing resilience, and real-world evidence capabilities to support sustainable launch and access

Leading organizations in the injectable SMA ecosystem demonstrate a consistent pattern of capabilities that translate into competitive advantage: deep expertise in advanced modalities, integrated clinical development pathways, and flexible manufacturing strategies. Companies that combine sustained investment in vector and oligonucleotide platform technology with robust pharmacovigilance systems are better positioned to navigate complex regulatory expectations and to generate the long-term safety data that payers increasingly require. Strategic partnerships-ranging from academic collaborations to contract manufacturing alliances-amplify capacity and accelerate clinical translation, while companies with early commitments to specialty pharmacy networks and center-of-excellence programs typically achieve smoother launches.

The ability to operationalize training programs for intrathecal administration, to scale cold-chain distribution, and to support homecare or clinic-based infusion alternatives separates organizations that can deliver at scale from those that face bottlenecks. Moreover, firms that proactively invest in real-world evidence generation, patient registries, and outcomes-based contracting frameworks cultivate stronger dialogues with payers and providers. Finally, nimble commercialization models that integrate field-based clinician education with digital patient-support services enhance adherence and retention in long-term follow-up programs, creating a virtuous circle of improved clinical outcomes and stronger value demonstration.

Practical and prioritized strategic moves that align clinical, operational, and commercial capabilities to accelerate access and ensure sustainable delivery of injectable SMA therapies

Industry leaders should prioritize an integrated approach that aligns clinical development with operational readiness and payer engagement to ensure durable access to injectable SMA therapies. First, embedding real-world evidence collection into post-approval programs and registries will strengthen value propositions and support outcome-based contracting, while also informing safety-monitoring protocols and long-term care planning. Second, expanding clinician training programs and certifying administration centers will reduce procedural variability and improve patient experience, especially for intrathecal administration which requires specialized expertise. Third, investing in distributed manufacturing and secondary supplier qualification can mitigate policy and tariff risk, shorten lead times, and support regional supply continuity.

Commercial strategies should include segmentation-aligned channel planning that recognizes differing logistics needs across hospital pharmacies, retail pharmacies, and specialty distribution partners, while simultaneously optimizing patient support programs to address adherence and infusion-site preferences. Collaborations with payers to design risk-sharing or milestone-based reimbursement models can lower barriers to access and align incentives around measurable patient outcomes. Finally, pursuing strategic partnerships for homecare infusion capabilities and telehealth-enabled follow-up will enhance care continuity for patients in dispersed geographies. These recommendations provide a pragmatic roadmap to translate clinical innovation into accessible, sustainable care pathways for patients living with SMA.

Transparent mixed-methods research approach combining primary stakeholder interviews, regulatory and clinical literature review, and expert validation to support actionable insights

This research synthesis is grounded in a mixed-methods approach that integrates primary qualitative insights with a rigorous review of clinical, regulatory, and operational sources. Primary inputs included structured interviews with clinicians experienced in intrathecal and intravenous administration, supply-chain executives, specialty pharmacy operators, and patient advocacy stakeholders, providing frontline perspectives on care pathways, training needs, and distribution challenges. Secondary research comprised a systematic review of peer-reviewed clinical studies, regulatory guidance documents, clinical trial registries, and reimbursement policy announcements to triangulate evidence on safety profiles, administration protocols, and payer expectations.

Data synthesis employed thematic coding of qualitative interviews to identify recurring operational constraints and strategic enablers, while documentary analysis informed comparative assessment of regional regulatory environments and distribution models. Where appropriate, findings were validated through expert panel review that included clinical and manufacturing specialists to ensure practical relevance. This methodology prioritizes transparency and reproducibility: core assumptions, source lists, and interview frameworks are documented in the methodological appendix, enabling readers to assess the robustness of the conclusions and to adapt the approach for internal decision-making processes.

A concise synthesis underscoring the necessity of cross-stakeholder alignment across clinical, manufacturing, and payer domains to realize sustained patient benefit from injectable SMA therapies

The injectable SMA therapeutic arena stands at an inflection point where scientific progress, delivery innovation, and system-level preparedness collectively determine patient access and long-term outcomes. Effective strategies require synchronizing clinical program design with manufacturing scale-up, distribution resilience, and payer-aligned evidence generation. Stakeholders that recognize the interdependencies between mechanism-specific clinical requirements, route-of-administration logistics, and care-environment readiness will be better equipped to translate therapeutic potential into meaningful patient benefit.

Moving forward, success will favor organizations that adopt proactive supply-chain strategies, invest in clinician training and center certification, and rigorously pursue real-world evidence that informs reimbursement conversations. By focusing on these domains, industry participants can strengthen the continuum from discovery to everyday clinical practice, ensuring that advances in antisense oligonucleotide therapies and gene therapies are realized as durable improvements in patient function and quality of life. The path ahead requires collaboration across payers, providers, manufacturers, and patient groups to build resilient systems that deliver innovative injectable therapies to those who need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Injections for SMA Market, by Mechanism Of Action

  • 8.1. Antisense Oligonucleotide Therapy
  • 8.2. Gene Therapy

9. Injections for SMA Market, by Route Of Administration

  • 9.1. Intrathecal Injection
  • 9.2. Intravenous Injection

10. Injections for SMA Market, by Indication

  • 10.1. Type I
  • 10.2. Type II
  • 10.3. Type III
  • 10.4. Type IV

11. Injections for SMA Market, by End User

  • 11.1. Clinics
    • 11.1.1. Ambulatory Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Injections for SMA Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Injections for SMA Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Injections for SMA Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Injections for SMA Market

16. China Injections for SMA Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Astellas Pharma Inc.
  • 17.6. Audentes Therapeutics, Inc.
  • 17.7. Audentes Therapeutics, Inc.
  • 17.8. Biogen Inc.
  • 17.9. Biohaven Pharmaceutical Holding Company Ltd.
  • 17.10. BridgeBio Pharma, Inc.
  • 17.11. Catalyst Pharmaceuticals, Inc.
  • 17.12. Cytokinetics, Inc.
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Genentech, Inc.
  • 17.15. Ionis Pharmaceuticals, Inc.
  • 17.16. NMD Pharma A/S
  • 17.17. Novartis AG
  • 17.18. Novartis Gene Therapies, Inc.
  • 17.19. Pfizer Inc.
  • 17.20. PTC Therapeutics, Inc.
  • 17.21. Regenxbio Inc.
  • 17.22. Sarepta Therapeutics, Inc.
  • 17.23. Scholar Rock, Inc.
  • 17.24. Shionogi & Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INJECTIONS FOR SMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INJECTIONS FOR SMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRATHECAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRATHECAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRATHECAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY TYPE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY AMBULATORY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY AMBULATORY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY AMBULATORY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. GCC INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GCC INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 141. G7 INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. G7 INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. NATO INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NATO INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 152. NATO INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INJECTIONS FOR SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA INJECTIONS FOR SMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA INJECTIONS FOR SMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA INJECTIONS FOR SMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA INJECTIONS FOR SMA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA INJECTIONS FOR SMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA INJECTIONS FOR SMA MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA INJECTIONS FOR SMA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)